“Monoclonal antibodies for treatment of bone marrow cancer. multiple myeloma".

“Monoclonal antibodies for treatment of multiple myeloma. Present status and aspects of effector mechanisms with emphasis on the CD38 antibody daratumumab ”. - DARA for myeloma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-005189-31-DK

Enrollment

Registered

2014-12-16

Start date

2014-12-16

Completion date

Unknown

Last updated

2017-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma MedDRA version: 19.1 Level: LLT Classification code 10028567 Term: Myeloma, malignant System Organ Class: 100000004864

Interventions

Product Name: Daratumumab Pharmaceutical Form: Solution for infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients that have been enrolled into a clinical trial MMY3003 for treatment of multiple myeloma Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria: Patients not elegible for MMY3003

Design outcomes

Primary

Measure	Time frame
Main Objective: To indentify factors that determine the activity of Daratumumab when used for treatment of multiple myeloma;Secondary Objective: To indentify factors that determine the activity of Daratumumab when used for treatment of multiple myeloma;Primary end point(s): Progression free survival;Timepoint(s) of evaluation of this end point: As defined in MMY3003	—

Secondary

Measure	Time frame
Secondary end point(s): Overall survival;Timepoint(s) of evaluation of this end point: As defined in MMY3003	—

Countries

Denmark, Netherlands

Contacts

Public ContactSponsor PI

Dept Hematology SLB Vejle

torben.plesner@rsyd.dk4579406313

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026